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Editorial on the Research Topic
Danger Signals Triggering Immune Response and Inflammation
The immune system detects “danger” through a series of what we call pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular pattern molecules (DAMPs), working in concert 
with both positive and negative signals derived from other tissues. PAMPs are molecules associated 
with groups of pathogens that are small molecular motifs conserved within a class of microbes. 
They are recognized by toll-like receptors (TLRs) and other pattern-recognition receptors. A vast 
array of different types of molecules can serve as PAMPs, including glycans and glycoconjugates. 
Bacterial lipopolysaccharides (LPSs), endotoxins found on the cell membranes of Gram-negative 
bacteria, are considered to be the prototypical class of PAMPs. LPSs are specifically recognized by 
TLR4, a recognition receptor of the innate immune system. Other PAMPs include bacterial flagellin 
(recognized by TLR5), lipoteichoic acid from Gram-positive bacteria, peptidoglycan, and nucleic 
acid variants normally associated with viruses, such as double-stranded RNA, recognized by TLR3 
or unmethylated CpG motifs, recognized by TLR9. DAMPs, also known as alarmins, are molecules 
released by stressed cells undergoing necrosis that act as endogenous danger signals to promote 
and exacerbate the immune and inflammatory response. DAMPs vary greatly depending on the 
type of cell (epithelial, mesenchymal, etc.) and injured tissue. Some endogenous danger signals 
include heat-shock proteins, high-mobility group box 1 (HMGB1), reactive oxygen intermediates, 
and extracellular matrix breakdown products such as hyaluronan fragments, neuromediators, and 
cytokines including the interferons. Non-protein DAMPs include ATP, uric acid, heparin sulfate, 
and DNA. Furthermore, accumulating evidence supports correlation between alarmins and changes 
in the microbiome. Increased serum or plasma levels of these DAMPs have been associated with 
many inflammatory diseases, including gastric and intestinal inflammatory diseases, graft-versus-
host disease (GVHD), sepsis and multiple organ failure, allergies particularly in the lungs, athero-
sclerosis, age-associated insulin resistance, arthritis, lupus, neuroinflammation/degeneration, and 
more recently in tumors, which is particularly interesting with the emergence of immunotherapies. 
Therapeutic strategies are being developed to modulate the expression of these DAMPs for the treat-
ment of these diseases.
A vast number of reviews have already been published in this area; thus, in an effort to not 
duplicate what has already been written, we will focus on recent discoveries particularly in disease 
models that are epidemic in Western society: intestinal chronic inflammatory diseases including 
GVHD and its relationship with the microbiome, chronic infectious diseases, allergies, autoimmune 
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diseases, neuroinflammation, and cancers. We will also focus on 
the basic cellular roles of macrophages, T cells, and B cells.
This research topic brings together 16 articles that provide 
novel insights into the mechanisms of action of DAMPs/alarmins 
and their regulation and subsequent immunologically driven 
responses. The take-home messages from these 16 studies are 
summarized below.
Two articles focused on the basic mechanisms of activation of 
macrophages and B cells by TLRs. Chu et al. showed in an original 
research article that the Fab fragment of a human anti-Siglec-9 
monoclonal antibody suppresses LPS-induced inflammatory 
responses in human macrophages, which has important thera-
peutic consequences for sepsis management. The mini-review 
by Suthers and Sarantopoulos explored the cross talk between 
TLR7/TLR9 and BCR signaling, which they suggest induces 
dangerous B cells. Although underexplored, it is now clear that a 
balance between TLR7 and TLR9 is pivotal in the development of 
B-cell autoreactivity, and one disease model to study this further 
is chronic GVHD, as the microenvironment after allogeneic 
hematopoietic stem cell transplantation contains large amounts 
of microbial-derived nucleic acids and B-cell-activating factor.
Five articles included in this research topic investigated the roles 
of PAMPs and DAMPs in the development of intestinal inflamma-
tion including acute GVHD. Pellegrini et  al. reviewed how the 
canonical and non-canonical activation of the NLR family pyrin 
domain containing 3 (NLRP3) inflammasome regulates tolerance 
and inflammation in the intestine. Indeed, NLRP3 has a dual role in 
the pathogenesis of bowel inflammation. In some studies, NLRP3 
has regulatory and reparative roles in the immune homeostasis 
and maintenance of the epithelial barrier integrity, whereas in 
others, overactivation of NLRP3 contributes to interruption of the 
intestinal immune balance. Lin et al. published an original article 
on how Helicobacter pylori, which infects more than half of the 
human population worldwide, activates HMGB1 expression, and 
recruits RAGE into lipids rafts to promote inflammation in gastric 
epithelial cells. In this translational work, the authors found that 
HMGB1 and RAGE expression levels are significantly greater in 
H. pylori-infected cells than in uninfected gastric cells. Blocking 
HMGB1 by a neutralizing antibody can abrogate H. pylori-elicited 
RAGE signaling by reducing nuclear factor (NF)-κB activation 
and interleukin (IL)-8 production. The current understanding 
and future perspectives of danger signals in GVHD were reviewed 
by Toubai et al. One interesting new finding in this field is the role 
of the HMGB1 receptor (Siglec-G)/CD24 axis in controlling the 
severity of GVHD (1). The mini-review by Apostolova and Zeiser 
summarizes the role of purine metabolites, particularly ATP/
ectonucleotidases as novel DAMPs, in the development of acute 
GVHD. These interactions are influenced by the intestinal micro-
biome, which has been particularly well explored. Slingerland 
et al. reviewed the role of the microbiome in intestinal diseases and 
other diseases such as circulatory, integumentary, musculoskeletal, 
respiratory, neuromuscular, and systemic conditions, focusing on 
clinical evidence and one potential therapeutic intervention. Two 
original papers looked at danger signals in relation to autoimmun-
ity development. Peng et al. showed increases in TLR activity and 
TLR ligands in patients with autoimmune thyroid diseases. Using 
peripheral blood mononuclear cells from 30 healthy controls, 36 
patients with untreated Hashimoto’s thyroiditis, and 30 patients 
with newly onset Graves’ disease, they showed that TLR2, TLR3, 
and TLR9 expression and activation are increased in patients 
with autoimmune thyroid diseases, suggesting a role for TLRs in 
the pathogenesis. Yun et al. showed that the HMGB1–CXCL12 
complex promotes T-cell infiltration in chronic experimental 
autoimmune uveitis. They demonstrated that at a very early stage 
of intraocular inflammation initiated by uveitogenic autoreactive 
T cells, synergism between HMGB1 and CXCL12 is crucial for 
the infiltration of inflammatory cells and that the induction of 
experimental autoimmune uveitis was significantly inhibited by 
a CXCR4 antagonist, AMD3100.
Three papers explored the role of danger signals in the brain. 
Terrando et  al. showed that HMGB1 is rapidly released after 
tissue trauma and its neutralization prevents postoperative 
neurocognitive dysfunction in a model of aged rats. Indeed, 
postoperative neurocognitive disorders are common complica-
tions in elderly patients following surgery or critical illness, and 
these findings offer a better understanding of the neurocognitive 
dysfunction and therapeutic options. Lin et al. studied another 
neuroprotective effect through the activation of the can-
nabinoid receptor-2 with a selective agonist, JWH133, and they 
showed the protection to be due to suppressed neuroinflam-
mation and upregulated expression of microglial macrophage 
M2-associated markers in an intracerebral hemorrhage model. 
Finally, Wilkins et al. reviewed the role of mitochondria-derived 
DAMPs in neurodegeneration. The roles of neuroinflammation 
in neurodegenerative diseases including Alzheimer’s disease 
(AD), Parkinson’s disease, and amyotrophic lateral sclerosis are 
increasingly appreciated, but the field is still in its infancy. Initial 
interest in neuroinflammation as a causative factor in AD was 
triggered by the reduced risk for AD in long-term non-steroidal 
anti-inflammatory drug users, which was later linked to the 
apolipoprotein E ε4 allele (2). Furthermore, genome-wide asso-
ciation studies identified a triggering receptor variant expressed 
on myeloid cells 2 (TREM2) as a causative factor for AD (3). 
Since these initial studies were published, much progress has 
been made to clarify how mitochondrial dysfunction plays a 
fundamental role, as elegantly reviewed by the group of Russell 
Swerdlow, a pioneer in the field (Wilkins et al.).
Two studies investigated the importance of immune homeo-
stasis disruption in lung diseases. Chen et al. demonstrated that a 
novel subset of IL-10-producing CD1dhiCD5+ regulatory B cells 
modulates immune homeostasis in patients with silicosis, a con-
dition of chronic inflammation and fibrosis of the lung. The study 
reported by Lin et al. showed that LPS can attenuate proallergic 
cytokines such as thymic stromal lymphopoietin (TSLP) and 
IL-33 in respiratory epithelial cells stimulated with polyI:C and 
human parechovirus. This work supports the “hygiene hypoth-
esis,” which claims that childhood exposure to environmental 
microbial products is inversely related to the incidence of allergic 
diseases in later life. It also suggests that in addition to therapeutic 
targeting of TSLP and IL-33, local application of non-pathogenic 
LPS may be a rational strategy to prevent allergies.
Interestingly, one of the mediators recently identified in 
the pathogenesis of allergies is IL-33. Undeniably, the serum 
stimulation-2 (ST2)/IL-33 axis has been found to be rooted in 
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the pathogenesis of an increasing number of diseases, and this is 
reviewed in a manuscript published by Griesenauer and Paczesny. 
Briefly, ST2, the IL-33 receptor, exists in two forms as splice 
variants: a soluble form (sST2), which acts as a decoy receptor, 
sequesters free IL-33, and does not signal, and a membrane-
bound form (ST2), which activates the MyD88/NF-κB signaling 
pathway to enhance mast cell, Th2, regulatory T cell, and innate 
lymphoid cell type 2 functions. Plasma/serum levels of sST2 are 
increased in patients with active inflammatory bowel disease 
(4), cardiac diseases (5), acute cardiac allograft rejection (6), and 
GVHD (7–14). The review also details the immune cells that 
express ST2 on their surface or secrete sST2 as well as the relevant 
signaling mechanisms. The ST2/IL-33 axis has recently been 
shown to be a potential novel checkpoint in the development 
of tumors, as reviewed by Wasmer and Krebs. Indeed, recent 
findings have shown a role of IL-33 in several cancers where 
it may exert multiple functions. The role of the ST2/IL-33 axis 
has been particularly well studied in colorectal cancer (15) and 
myeloproliferative neoplasms (16). Importantly, IL-33 could be 
used as potential tumor biomarker or therapeutic target.
In summary, the reviews and original articles collected for this 
research topic of Frontiers in Immunology convey to readers the 
multiplicity and implications of PAMPs/DAMPs/alarmins and 
their regulators in the development of inflammatory diseases. 
Importantly, learning from these mechanisms of action, each 
group of investigators has proposed novel targeted treatments.
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